PanGen Biotech Inc. (KOSDAQ:222110)
South Korea · Delayed Price · Currency is KRW 5,170.00
+150.00 (2.99%)
At close: Aug 11, 2026
PanGen Biotech Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 69,870 | 75,568 | 73,520 | 73,462 | 69,405 | 99,783 | |
Market Cap Growth | -16.76% | 2.79% | 0.08% | 5.85% | -30.44% | 1.96% |
Enterprise Value | 58,173 | 63,258 | 69,814 | 74,767 | 67,446 | 92,638 |
Last Close Price | 5170.00 | 5600.00 | 5700.00 | 6880.00 | 6500.00 | 9350.00 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 35.53 | 36.85 | 77.91 | - | - | - |
Forward PE | - | 91.30 | 91.30 | 91.30 | 91.30 | 91.30 |
PS Ratio | 5.10 | 5.63 | 5.01 | 10.04 | 10.68 | 12.57 |
PB Ratio | 2.28 | 2.53 | 2.95 | 5.85 | 4.03 | 4.73 |
P/TBV Ratio | 2.36 | 2.62 | 3.05 | 6.29 | 4.10 | 4.80 |
P/FCF Ratio | - | - | 27.99 | - | - | - |
P/OCF Ratio | - | 398.12 | 24.61 | - | - | - |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 4.24 | 4.72 | 4.76 | 10.22 | 10.38 | 11.67 |
EV/EBITDA Ratio | 21.02 | 21.29 | 28.06 | - | - | - |
EV/EBIT Ratio | 45.18 | 42.00 | 68.43 | - | - | - |
EV/FCF Ratio | - | - | 26.58 | - | - | - |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.03 | 0.03 | 0.03 | 0.16 | 0 | 0.89 |
Debt / EBITDA Ratio | 0.36 | 0.32 | 0.33 | - | - | - |
Debt / FCF Ratio | - | - | 0.31 | - | - | - |
Net Debt / Equity Ratio | -0.38 | -0.43 | -0.43 | 0.14 | -0.05 | -0.26 |
Net Debt / EBITDA Ratio | -4.23 | -4.32 | -4.26 | -0.69 | 0.28 | 3.08 |
Net Debt / FCF Ratio | 17.38 | 34.43 | -4.04 | -0.47 | 0.20 | 1.14 |
Asset Turnover | 0.43 | 0.42 | 0.57 | 0.35 | 0.20 | 0.20 |
Inventory Turnover | 1.30 | 1.35 | 1.48 | 0.94 | 1.07 | 1.82 |
Quick Ratio | 5.80 | 5.64 | 4.98 | 0.42 | 1.55 | 1.28 |
Current Ratio | 8.67 | 8.43 | 7.16 | 1.72 | 7.59 | 1.57 |
Return on Equity (ROE) | 7.33% | 7.48% | 5.04% | -30.14% | -23.46% | -18.75% |
Return on Assets (ROA) | 2.50% | 2.98% | 2.49% | -12.75% | -8.97% | -5.17% |
Return on Invested Capital (ROIC) | 7.13% | 9.52% | 6.69% | -27.46% | -28.62% | -22.21% |
Return on Capital Employed (ROCE) | 4.20% | 5.00% | 3.70% | -28.10% | -23.50% | -14.10% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 10, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 2.96% | 2.71% | 1.28% | -6.11% | -6.48% | -3.32% |
FCF Yield | -0.96% | -0.49% | 3.57% | -5.27% | -6.10% | -4.76% |
Buyback Yield / Dilution | -13.86% | -17.05% | -7.68% | -0.13% | -4.47% | -6.02% |